Mario Gamero, El Salvador
Hospital Nacional de Niños Benjamin Bloom San SalvadorAuthor Of 2 Presentations
INVASIVE NON-VACCINE SEROTYPE DISEASE AFTER THE INTRODUCTION OF PCV13 IN EL SALVADOR (ID 889)
Abstract
Background
PCV 7 and 13 were introduced in El Salvador in 2010 and 2011 respectively, with a decrease of more than 85% of invasive infections. However, an increase in replacement strains has been found that behaves highly invasive with high lethality.
Methods
60 patients admitted to Hospital de Niños Benjamin Bloom from January 2011 to December 2017 with invasive infections due to serotypes (S) not contained in the vaccine were described.
Results
60 records of children under 14 years of age with invasive pneumococcal infection and positive cultures in sterile fluids were reviewed, empyema pneumonia 20 (33%); meningitis 11 (18%); sepsis 12 (20%) and septic shock 12 (20%); pneumonia 5 (8%). Majorly responsible replacement serotypes: 10 A, 15 A, 11, 12 A, 18 A, 10 B, 8, 14 F, 15 C, 12 A. of the total of 33 (55%) cases. 30% overall mortality.
Conclusions
The Valente 13 vaccine has been highly effective in El Salvador, but non-vaccine serotypes have produced Invasive Infections with a high percentage of mortality. It is important epidemiologically to report the phenomenon of replacement.
REDUCTION OF PNEUMONIA WITH EMPYEMA AFTER THE INTRODUCTION OF THE PNEUMOCOCCAL CONJUGATE VACCINE IN EL SALVADOR (ID 756)
Abstract
Background
PCV has effectiveness in pneumonia with empyema (PE), PCV was introduced in 2010 (PCV7 3 + 1) and 2011 (PCV13 2 + 1) with coverage of 94%. In the pre vaccinations era (2002-2009) 6 cases/year were reported, in the post PCV7 stage there was no reduction in cases and in 2013 the reduction was 67%. The objective was to describe the impact of the PCV13 on the reduction of pneumococcal disease in the National Children's Hospital.
Methods
Analytical cross-sectional retrospective study. The total hospitalized patient with PE were reviewed (2002- 2018) with positive culture in pleural fluid to pneumococcus, epidemiological variables and vaccination status, 82 cases were reviewed.
Results
In the prevaccine period 49 cases were reported (2002-2009), in the post implementation (2010-2012) 28 cases, and from 2013-2018 5 were described, 4 are serotypes not contained in the vaccine (11, 13, 12A) and a case of 19F in a 12-year-old child with a single dose of PCV13.
Conclusions
After 9 years of PCV use in El Salvador there has been a decrease in cases of PE